| |
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome overcome these challenges using AI cloud infrastructure and advanced machine learning tools.
|
|
Today’s Big NewsFeb 6, 2025 |
|
Wednesday, February 26, 2025 | 11am ET / 8am PT Discover how the convergence of spatial biology, AI, and computational tools is transforming cancer research. This webinar explores high-multiplex spatial analysis, tumor heterogeneity, and advances in precision medicine, reshaping drug development. Register now to learn how these innovations are driving breakthroughs in oncology.
|
|
| By Kevin Dunleavy Just nine months after announcing a massive plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal to save even more money. |
|
|
|
By Gabrielle Masson Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide-seller Novo Nordisk—with its blockbuster molecule tirzepatide. Now, with a pipeline chock full of numerous incretin therapies, the big pharma's new strategy will be to test some of those drugs across neurology and immunology indications. |
By Dave Muoio Managers across the health agencies were tasked with categorizing their probationary workers to determine those who were not mission critical, according to two new media reports citing internal sources. |
By Conor Hale The “New BD,” as the company describes it, will continue on as a pure-play medtech with enterprises in medical essentials, interventional devices and connected care. |
|
Thursday, February 27, 2025 | 2pm ET / 11am PT The quest to discover biomarkers for therapeutic response through traditional genomic sequencing and other omic approaches has yet to deliver clinically actionable tools for most patients. Don’t miss this compelling discussion on how cutting-edge glycoproteomic technologies are unlocking new clinical insights.
|
|
By Darren Incorvaia After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is climbing closer to its goal of accelerated approval by unveiling data showing the drug met its primary safety endpoints and reduced key biomarkers of the disease. |
By Nick Paul Taylor Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease, according to Spherix Global Insights. |
By Angus Liu As AstraZeneca faces an ongoing investigation into alleged illegal importation of drugs in China, the company's China business logged a sales decline in the fourth quarter of 2024. |
By Nick Paul Taylor Eli Lilly has thinned its pipeline in two critical therapeutic areas, axing clinical-phase Alzheimer’s disease and obesity candidates as part of its quarterly clear-out. Besides those cuts, the company removed eczema and heart failure prospects from its pipeline. |
By Conor Hale LinusBio aims to help physicians rule out the likelihood of autism developing in infants and toddlers under age three, and as young as one month old. |
By Nick Paul Taylor Invivyd has teamed up with professional football coach Jim Harbaugh to tackle COVID-19 complacency. The biotech, which has seen sales of its COVID-19 product fall well short of expectations, is working with Harbaugh to raise awareness of how immunocompromised people can reduce the threat of the virus. |
By Angus Liu The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to disrupt the pre-exposure prophylaxis field with a twice-yearly injection. But GSK, with a bimonthly option, doesn’t think its rival can hog the entire long-acting market. |
By Gabrielle Masson Pfizer is laying down new pieces for its leadership team structure, selecting Jeffrey Legos, Ph.D., to replace interim Chief Oncology Officer Roger Dansey, M.D. |
By Fraiser Kansteiner Thanks to impressive sales growth across multiple therapeutic areas in 2024, Eli Lilly seems to have assuaged investor concerns that its incretin drugs for diabetes and obesity were reaching a sales plateau. |
By Nick Paul Taylor,James Waldron AstraZeneca has ended development of its oral factor D inhibitor vemircopan, triggering a $753 million impairment charge as the drugmaker reevaluated the worth of its Alexion acquisition. The drugmaker took another charge in relation to last year’s $2 billion push into radiopharmaceuticals. |
Fierce podcastsDon’t miss an episode |
| | As the first two weeks of his second term showed, keeping up with Trump’s actions—and their ramifications—requires full-time focus. A policy expert breaks down how Congress might approach reform in 2025. |
|
|---|
|
|
| WhitepaperThis paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
